A Phase I/II, Open-Label Dose Escalation Trial to Evaluate the Safety and Efficacy of Two Dose Levels of PNEUMOSTEM in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD)
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2018
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Adverse reactions
- Sponsors Medipost
- 14 Aug 2018 Status changed from active, no longer recruiting to completed.
- 18 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 03 May 2016 According to Medipost media relese, 90% of the study is complete.